Medical imaging advanced analytics company IXICO (AIM: IXI) announced on Wednesday that it is collaborating with IMEKA Solutions Inc to provide access to Imeka's white matter imaging services for Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, among other CNS indications.
The collaboration streamlines procurement processes for IXICO's global biopharma clients, enhancing access to advanced AI tools for white matter imaging.
White matter imaging is increasingly vital for neuroinflammation and axonal integrity assessments in AD and MS clinical trials, along with other CNS indications.
IXICO aims to revolutionise neurological disease therapy advancements by providing valuable insights through data analytics and AI-driven medical image analysis.
The company's remote access technology platform enables scalable data analytics deployment, optimising drug development investments and reducing clinical trial risks for pharmaceutical clients.
Imeka, a leader in white matter microstructure imaging, offers advanced MRI processing and AI capabilities to facilitate novel insights for research and clinical communities.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline